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SYNOPSIS 
The thesis entitled “Total synthesis of fluvirucinine A1, formal synthesis of amphidinin 
B and first stereoselective total synthesis of gallicynoic acids G and H” is divided into 
three chapters. 
Chapter I: Total synthesis of Fluvirucinine A1 
This chapter dealt with the total synthesis of fluvirucinine A1 by a combination of chiron 
approach and asymmetric synthesis. 
Fluvirucins A1, A2, B1, B2, B3, B4 and B5 were isolated by Naruse et al.1 in 1991 
from the fermentation broth of actinomycete strains. These are 14-membered macrolactam 
antibiotics and potent inhibitors of influenza A virus type A strain in Madin Darby Canine 
Kidney (MDCL) cells.1 
  In addition to strong activity against influenza A virus these antibiotics have 
inhibitory activity against certain gram positive bacteria, anaerobic bacteria and fungi.1 
Later the structure and stereochemistry of fluvirucins was established by Naruse et al.2,3 in 
1991 based on spectroscopic analysis and chemical transformations.  
Fluvirucinine A1 1 is aglycone of fluvirucin A1. The absolute stereochemistry of 14-
membered macrolactam fluvirucinine A1 1 was established3 as 2R, 3S, 6R, 10S.  It has 
potent inhibitory activity against influenza A virus.2 
Figure 1: Fluvirucinine A1 1
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The retrosynthetic strategy envisioned for 1 is delineated in Scheme 1. 
Fluvirucinine A1 1 could be realized by ring-closing metathesis4,5 of bis-olefin 2 followed 
by hydrogenation, which inturn could be envisaged from fragments 3 and 4. Both 
fragments 3 and 4 inturn could be readily accessed from the commercially available (S)-
Roche ester 5.  
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Scheme 1: Retrosynthetic analysis of f luvirucinine A1 1
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 The synthesis of 3 commenced with known allylic alcohol 66 that was easily 
accessed in four steps from 5 (Scheme 2). Treatment of 6 with imidazole, triphenyl 
phospine and iodine in THF produced allyl iodide 7 in 76% yield and set the stage for 
highly diastereoselective Evans asymmetric alkylation7 to install the C10 ethyl group with 
the desired stereochemistry. 
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Scheme 2: Reagents and conditions: (a) PPh3, I2, imidazole, THF, 0.5h, 76%; (b) 8, LiHMDS, -78 oC, 1h, 7 af ter 6h, -20 oC,
14h; (c) NaBH4, MeOH, 0 oC to r.t., 1h, 81%; (d) (i) IBX, CH2Cl2, DMSO, 0 oC to r.t., 4h; (ii) Ph3P=CHCOOMe, C6H6, ref lux, 4h,
85% (over two steps) (e) H2, Pd/C, EtOAc, 4h, 92%; (f ) DIBAL-H, CH2Cl2, -40 oC, 1h, 84%; (g) (i) TsCl, Et3N, CH2Cl2, 0 oC to
r.t., 3h; (ii) NaN3, DMF, 80 oC, 4h, 85% (over two steps); (h) (i) H2, Pd/C, EtOAc, 9h; (ii) (Boc)2O, Et3N, CH2Cl2, 1h, 83% (over
two steps); (i) TBAF, THF, 3h, 78%; (j) (i) (COCl)2, DMSO, Et3N, -78
oC, 1h (ii) Ph3PMeI, KO
tBu, THF, -10 oC to r.t, 4h, 65%
(over two steps).
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Synthesis of C5-C13 fragment 3
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 Accordingly, N-butyryl oxazolidinone 8 was alkylated with allylic iodide 7 to afford 
the corresponding ethylated product 9 in 86% yield and in high diastreoselectivity. An 
excess of enolate (1.6 eq) was essential to achieve completion of the reaction. The 
diastereoselectivity was assigned by 1H and 13C NMR of crude reaction mixture. Next, 
reductive cleavage (NaBH4/MeOH/0 oC to r.t./1h) of the chiral auxiliary in 9 afforded 10 
(81%). Alcohol 10 on oxidation with IBX furnished the corresponding aldehyde, which 
was exposed to Wittig olefination to afford 11 (85% yield over two steps). Compound 11 
was subjected to catalytic hydrogenation (Pd/C in EtOAc) under hydrogen atmosphere to 
gave the corresponding saturated ester 12 (92%), which upon treatment with DIBAL-H in 
CH2Cl2 gave alcohol 13 (84%). Alcohol 13 was converted to its corresponding tosylate 
(TsCl/Et3N/CH2Cl2/0 oC to r.t./3h), which was subsequently transformed into the 
corresponding azide 14 (85%, over two steps) under conventional conditions 
(NaN3/DMF/80 oC/4h). The resulting azide 14 was converted to N-Boc derivative 15 in 
83% yield by a two-step process, firstly reduction of the azide to the amine via 
hydrogenation (H2-Pd/C/EtOAc/r.t./9h) followed by the bocylation reaction 
{(Boc)2O/Et3N/CH2Cl2/0 oC to r.t./1h}. Desilylation of 15 with TBAF in THF afforded 
alcohol 16 (78%). Alcohol 16 on oxidation under Swern conditions followed by one 
carbon Wittig olefination furnished the olefin 17 in 65% yield over two steps. 
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Scheme 3: Reagents and conditions: (a) (-)-DIPT, Ti(OiPr)4, CHP, CH2Cl2, -20 oC, 5h, 86%; (b)
(i) PPh3, I2, imidazole, THF, 0.5h; (ii) Zn, EtOH, 80 oC, 3h, 78% (over two steps) (c) NaH,
PMBBr, THF, 0 oC to r.t., 14h, 74%; (d) TBAF, THF, 3h, 79%; (e) (i) (COCl)2, DMSO, Et3N, -78
oC, 1h; (ii) NaClO2, NaH2PO4. 2H2O, 2-Methyl-2-butene, tBuOH (1:3), 0 oC to r.t., 12h, 75%
(over two steps).
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Synthesis of C1-C4 fragment 4
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 As depicted in Scheme 3, the synthesis of acid 4 began from 66, which on Sharpless 
asymmetric epoxidation6 with (-)-DIPT, Ti(OiPr)4 and CHP in CH2Cl2 at -20 °C afforded 
epoxy alcohol 18. The alcohol 18 on treatment with imidazole, PPh3 and I2 in THF 
converted into iodo-derivative, which was treated with Zn in ethanol8 to give allylic 
alcohol 19 (78% yield over two steps). Later, alcohol 19 was protected as its PMB ether 20 
(NaH/PMBBr/THF/ 0 oC to rt/14h, 74%). Silyl deprotection of 20 in presence of TBAF in 
THF afforded primary alcohol 21 (79%). The oxidation of the resultant primary alcohol 21 
under Swern conditions furnished the aldehyde, which on subsequent oxidation9 
(NaClO2/NaH2PO4/2-methyl-2-butene/12h) afforded acid 4 (75%). 
Compound 17 was treated with TFA in CH2Cl2 to liberate the free amine 3 which 
was immediately used for the amidation reaction (Scheme 4). With the requisite fragments 
3 and 4 in hand, the coupling reaction was undertaken. 
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Synthesis of 1
Scheme 4: Reagents and conditions: (a) TFA, CH2Cl2, DIPEA, 0 oC, 15 min; (b) EDCI, HOBT,
DIPEA, CH2Cl2, 98% (over two steps) (c) Grubbs-II, CH2Cl2, 45
oC,12h, 79%; (d) Pd/C, EtOAc,
3h, 89%.
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Gratifyingly, the reaction proceeded smoothly by treating the acid 4 with 
EDCI/HOBT/DIPEA followed by addition of amine 3 to afford the desired coupled 
product 2 in 98% yield. The resulting diene 2 was exposed to the RCM reaction using 
Grubbs-II catalyst in refluxing dichloromethane to produce macrolactam 22 (79%) as an 
E/Z mixture. Since the isomeric status was irrelevant, no attempts were made to purify 
compound 22 into separate entities. Finally, fluvirucinine A1 1 was obtained by hydrogen- 
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nation reaction (H2-Pd/C-/EtOAc/r.t./3h) wherein both the saturation of the C4-C5 olefinic 
bond and PMB deprotection occurred in one-pot. Spectroscopic data (1H and 13C NMR) 
and specific rotation of the synthetic material 1 was in good agreement with the reported 
data in the literature.1-3  
In summary, a stereoselective synthesis of 1 from the common intermediate 6,6 
using Evans asymmetric alkylation,7 Sharpless asymmetric epoxidation,6 amidation and 
RCM4,5 as a key steps in an overall yield of 10.5% was described in this chapter.  
Chapter II: Formal synthesis of Amphidinin B 
This chapter dealt with the formal synthesis of amphidinin B. 
Amphidinin B 23, a linear polyketide was isolated from the dinoflagellate 
Amphidinium sp. (strain number Y-56) by Kobayashi and co-workers (Figure 2).10 
Amphidinin B 23 showed potent activity against MCF-7 (breast cancer cell line) about 100 
times better activity11 than its cyclic analog amphidinolide T1.12 The structure of 
amphidinin B 23 was elucidated10 based on spectral techniques COSY, HOHAHA, 
HMBC. The absolute stereochemistry10 of Amphidinin B 23 was determined to be 2R, 6R, 
11S, 16S, 17S,19S based on Mosher’s ester method.                                 
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O
Figure 2: Amphidinin B 23
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  Amphidinin B 23 contains a core tri-substituted tetrahydrofuran skeleton with a 
chiral side-chain at C16. The side chain is embedded with an exo methylene, two branched 
methyl groups, a propyl and an ester linkage, one carboxyl group while another methyl 
group adorns at C17 on the tetrahydrofuran skeleton. Also, C19 is substituted by an ethanoic 
acid moiety.                            
As outlined in Scheme 5, the retrosynthetic analysis of 23 reveals that it could be 
obtained from acid 25 and alcohol 26 by Yamaguchi esterification.13 Both the fragments  
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25 and 26 inturn could be accessed from commercially available geraniol 27 and mono-
PMB protected 1,4-butane diol 2814 respectively by suitable transformations. 
Scheme 5: Retrosynthetic analysis of Amphidinin B 23
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Thus, the synthesis of tetrahydrofuran fragment 25 commenced from known diol 
2915 which inturn obtained from geraniol 27 (Scheme 6). Oxidative cleavage of 29 with 
NaIO4 gave the corresponding aldehyde which was reduced (NaBH4/MeOH/0 ºC) to 
furnish alcohol 30 (81% yield over two steps). The alcohol 30 was protected as its TBDPS 
ether by treating with imidazole and TBDPSCl in CH2Cl2 to afford 31 in 78% yield. 
Ozonolysis of olefin 31 in CH2Cl2 followed by Wittig olefination in benzene 
afforded 32 (74%) as E-isomer exclusively. Reduction of the olefin 32 with 
NiCl2.6H2O/NaBH4 furnished the saturated ester 3316 (90%). The ester 33 was partially 
reduced (DIBAL-H/CH2Cl2/-78 oC/1h) to aldehyde 35 (74%). 
Aldehyde 35 was then subjected to non-Evans syn-aldol17 with thiazolidine-2-
thione 34, generating secondary alcohol 36 (75%), whose diastereoselectivity was 
measured by LCMS (dr, 96.515:3.485) {Column: XDB-C18, acetonitrile:water (70:30), 
flow rate:1 mL/min, 210 nm, tr(major) = 1.712 min, tr(minor) = 3.383 min}. The resulting  
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Synthesis of C10-C21 fragment 25
Scheme 6: Reagents and conditions: (a) (i) NaIO4, sat. NaHCO3 soln, acetone:H2O (5:1), 0 oC, 4h; (ii) NaBH4, MeOH, 0 oC to
r.t., 1h, 81% (over two steps); (b) TBDPSCl, imidazole, CH2Cl2, r.t., 2h, 78%; (c) (i) O3, CH2Cl2, dimethylsulphide, -78 oC, 15
min; (ii) Ph3P=CHCOOEt, benzene, reflux, 10 min, 74% (over two steps); (d) NaBH4, NiCl2.6H2O, MeOH, 0
oC to r.t., 4h, 90%;
(e) DIBAL-H, CH2Cl2, -78 oC, 1h, 74%; (f ) 34, TiCl4, CH2Cl2, 0 oC, 15 min, iPr2EtN, 20 min, then cooled to -78 oC, 35, -78 oC to
r.t., 2h, 75%; (g) TBSOTf , 2,6-lutidine, CH2Cl2, 0 oC, 10 min, 82%; (h) LiBH4, MeOH, 0 oC to r.t., 30 min, 74%; (i) (i) (COCl)2,
DMSO, Et3N, -78 oC, 2h, 84%; (ii) 38, NaHMDS, THF, -78 oC, 30 min., aldehyde, -78 oC to r.t., 4h, 74%; (j) BH3.SMe2,
cyclohexene, THF, 0 oC, 2h, 40, 0 oC to r.t., 3h, 0 oC, NaOH-H2O2, 79%; (k) (i) (COCl)2, DMSO, Et3N, -78 oC, 2h; (ii)
Ph3P=CHCOOMe, benzene, ref lux, 2h, 78% (over two steps); (l) PPTS, MeOH, 0 oC to rt, 12h, 75%; (m) NaOMe, MeOH, -15 oC,
12h, 81%; (n) DIBAL-H, CH2Cl2, -40 oC, 1h, 78%; (o) NaH, PMBBr, THF, 0 oC to r.t., 6h, 80%; (p) TBAF, THF, 3h, 0 oC to r.t.,
74%; (q) TEMPO, PhI(OAc)2, CH2Cl2:H2O (1:1), 0
oC to r.t., 6h, 84%.
anti/ syn (94:6)
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secondary alcohol was protected as silyl ether18 (TBSOTf/2,6-lutidine/CH2Cl2/0 oC) 37 
(82%). Reductive cleavage of the auxiliary19 with LiBH4 afforded alcohol 39 (74%). 
Alcohol 39 was oxidized under Swern conditions to the corresponding aldehyde, which  
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was subjected to Julia olefination20  with 5-(methyl sulfonyl)-1-phenyl-1H-tetrazole 38 
using sodium hexamethyldisilazide (NaHMDS) as base in THF at -78 oC to afford alkene 
40. Alkene 40 underwent hydroboration (BH3.SMe2/cyclohexene/ H2O2/ NaOH) to afford 
alcohol 41 (79%). The Oxidation of 41 under Swern conditions provided the corresponding  
aldehyde, which was exposed to Wittig olefination to afford 42 (78% yield over two steps) 
as the sole product. The coupling constants of the olefin  J = 15.4 Hz as a doublet revealed 
the E-isomer. The Oxa-Michael reaction precursor 43 was obtained by selective 
deprotection of TBS ether21 with PPTS in MeOH. Oxa-Michael reaction22 
(NaOMe/MeOH/-15 oC/12h) of 43 afforded 44 (81%) in 94:6 selectivity in favor of trans-
isomer (major).  
The ratio was measured by HPLC. The two diastereoisomers of the compound 44 
were separated by preparative HPLC {Column: XDB-C 18, 20% water in acetonitrile, flow 
rate:1 mL/min, 210 nm, tr(major) = 1.595 min, tr(minor) = 1.210 min}. The 
stereochemistry at the newly formed C2 stereocenter in 44 (major) during Oxa-Michael 
addition reaction was relatively assigned as ‘anti’ to the existing C5 stereocenter, as 
evidenced by NOE experiments. 
O
CH3
OTBDPSMeOOC
H
H H
NOE
NOE
Figure 3: NOE correlations of compound 44  
 Subsequent transformations on 44 led to 25 which was already reported in the 
literature;11 thus, absolute configuration at C2 was assigned as ‘R’. Accordingly, treatment 
of ester 44 with DIBAL-H at -40 oC furnished alcohol 45 (78%), which on reaction with 
PMBBr (NaH in THF) afforded PMB ether 46 (80%). Desilylation of 46  with TBAF in 
THF afforded alcohol 47 (74%), which on subsequent oxidation with TEMPO and BAIB23 
furnished acid 2511 (84%). The spectroscopic data (1H and 13C NMR) and specific rotation 
of 25 were in good agreement with the reported data.11  
The synthesis of fragment 26 commenced with compound 48 which was 
synthesized as reported in the literature24 (Scheme 7). Secondary hydroxyl group in 48 was  
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protected as its tert-butyldimethylsilylether 49 (76%). Compound 49 on hydrogenation 
over Pd/C in EtOAc  afforded alcohol 50 (78%). Alcohol 50 underwent Swern oxidation 
conditions to afford aldehyde, which was subjected to Mannich reaction conditions25 
(CH2Br2/Et2NH/55 oC/1.5h/r.t., aldehyde/5 min), followed by DIBAL-H reduction to 
afford alcohol 52 (66%). Treatment of 52 with imidazole, triphenylphosphine in presence 
of iodine in THF produced allyl iodide, which on Evans alkylation7,26 with N-propionyl 
oxazolidinone 51 afforded 53 (75%) as a single isomer as evidenced from 1H or 13C NMR 
of crude reaction mixture. Reductive cleavage of the chiral auxiliary using LiBH4 in 
MeOH furnished alcohol 54 (82%), which was protected (NaH/BnBr/THF/0 oC to rt/2h) as 
its benzyl ether 55 (77%). Deprotection of 55 with TBAF in THF produced 2611 (71%). 
The spectroscopic data (1H and 13C NMR) and specific rotation of 26 was in good 
agreement with the reported data.11 
Scheme 7: Reagents and conditions: (a) TBSCl, imidazole, CH2Cl2, 0 oC to r.t., 2h, 76%; (b) H2, Pd/C, EtOAc, 12h, r.t.,
78%; (c) (i) (COCl)2, DMSO, Et3N, -78 oC, 2h, 91%; (ii) Et2NH, CH2Br2, 55 oC, 1.5h, r.t., aldehyde, 5 min, 66%; (iii) DIBAL-
H, CH2Cl2, -40 oC, 30 min, 80%; (d) (i) PPh3, I2, imidazole, THF, 0 oC, 10 min, 73%; (ii) 31, LiHMDS, -78 oC, 1h, allylic iodo
compound, -78 to -20 oC, 12h, 75% ; (e) LiBH4, MeOH, 0 oC to r.t., 30 min, 82%; (f ) NaH, BnBr, THF, 0 oC to r.t., 2h, 77%; (g)
TBAF, THF, 3h, 0 oC to r.t., 71%.
PMBO
OH PMBO
OH
PMBO
OTBS
HO
OTBS
HO
OTBS OTBS
O
NO
Bn
O
OTBS
HO
OH
BnO
OTBS
BnO
26
28 48 49
50 52
51
53
ref : 25 b
d
f g
a
54
O
NO
Bn
O
55
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With the requisite fragments 25 and 26 in hand,  coupled the two fragments using 
an intermolecular Yamaguchi esterification (Scheme 8).11,13 Esterification of 26 with the 
mixed anhydride prepared from acid 25 and 2,4,6-trichlorobenzoyl chloride, iPr2NEt in 
THF in the presence of DMAP in toluene afforded 24 (81%). The spectroscopic data (1H 
and 13C NMR) and specific rotation of 24 was in good agreement with the reported data.11 
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 Thus, synthesis of ester 24 concludes the formal synthesis of 23 since transformation of 
24 into 23 was already reported.11 
O OH OBn
O
PMBO
+
HO
25 26
O O
OBn
O
PMBO
Amphidinin B 23
Formal synthesis of 23
24
a
Scheme 8: Reagents and conditions: 2,4,6-Cl3PhCOCl, iPr2NEt, 10h, DMAP, toluene, 24h, 25 oC, 81%.
Ref. 11
 
In summary, formal synthesis of 23 from commercially available geraniol 27 and 
mono-PMB ether of 1,4-butane diol 2814 using Sharpless asymmetric epoxidation,15  non-
Evans aldol,17 Julia olefination,20 Oxa-Michael,22 Keck allylation,24 Mannich reaction,25 
Evans asymmetric alkylation7,26  and Yamaguchi esterification11,13  as the key steps was 
discussed in this chapter. 
Chapter III: First stereoselective total synthesis of Gallicynoic acids G and H 
This chapter dealt with the total synthesis of gallicynoic acids G and H.  
Gallicynoic acids G 56 and H 57 (Figure 4) were isolated from a culture of the 
basidiomycete Coriolopsis gallica27 along with gallicynoic acids A-F, I, these are 
acetylenic acids possessing one or more hydroxyl groups and/or olefin moiety. Acetylenic 
acids dislpay important biological activities such as anticancer, antibacterial, antimicrobial, 
antitumor, anti HIV and antifungal activities.28-37 
OH
OH
OH
O
OH
OH
OH
O
Gallicynoic acid G 56 Gallicynoic acid H 57
Figure 4: Gallicynoic acids G 56 and H 57  
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The structure and absolute stereochemistry of gallicynoic acids A-I were elucidated 
based on spectroscopic analysis and chemical transformations.27   
                    The retrosynthetic analysis for 56 and 57 is depicted in Scheme 9. It shows 
that 56 and 57 could be obtained from ynones 58/59 by asymmetric reduction. These 
ynones in turn could be envisaged through a convergent synthesis, from the nucleophilic 
addition reaction of alkyne 6038c, 38d with aldehydes 6139/6240 and followed by the oxidation 
of the resultant hydroxy group. The protected hydroxyl alkyne 60 utilized as a common 
intermediate for the construction of the acetylene part of 56 and 57. 
OH
OH
OH
O
n
OTBS
O
OPMB
OTBS
OHC
OPMB OHHOHO
61 n = 1
62 n = 5
+
56 n = 1
57 n = 5
58 n = 1
59 n = 5
60
n
63
Scheme 9: Retrosynthetic analysis of gallicynoic acids G 56 and H 57
n
n = 1
n = 5
n
 
Accordingly, synthesis of gallicynoic acid G 56 and H 57 commenced with the 
known protected hydroxyl alkyne 60 (Scheme 10). The enantiopure hydroxy alkyne 
6039b,39d was accessed by a modified literature route via the Sharpless asymmetric 
epoxidation protocol and the structure was confirmed by comparing its analytical data with 
reported values. 
To prepare alkyne 60,  propargyl alcohol 63 was subjected to butylation with n-butyl 
bromide in liquid NH3 and Li at – 33 oC to afford 6441 and then  reduction by LiAlH4 41b to 
give stereochemically pure (E)-alkene 65 in 90% yield. Exposure of the ensuing allylic 
alcohol to Sharples epoxidation [(-)-DIPT/Ti(OiPr)4/cumene hydroperoxide/CH2Cl2/-20 oC] 
furnished epoxy alcohol 66 (90%).42 Epoxide 66 was chlorinated with Ph3P in CCl4 and 
subjected to base induced double elimination38b (LDA/THF) to afford chiral propargylic 
alcohol 6738c,38d in 65% yield. Further, the free hydroxy group of alkyne 67 was protected as 
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 its tert-butyl dimethyl silyl ether 60 (TBSCl/imidazole/CH2Cl2/0 oC/r.t./2h/78%) (Scheme 
10). 
Scheme 10: Reagents and conditions. (a) Li, liq. NH3, Fe(NO3)3, HMPA, THF, C4H9Br,
-33 oC, 6h, 75%; (b) LiAlH4, THF, 0 oC- ref lux, 5h, 90%; (c) (-)-DIPT, Ti(iOPr)4, CHP,
CH2Cl2, -22
oC, 5h, 90%; (d) (i) Ph3P, NaHCO3 (cat), CCl4, ref lux, 2h, 84%, (ii) n-BuLi, DIPA,
THF, -40 oC, 1h, 75%; (e) TBSCl, imidazole, CH2Cl2, 0 oC - r.t., 2h, 78%.
OH
OH
OH
OH
O OH OTBS
63 64 65
66 67 60
a
Synthesis of fragment 60
b c
d e
 
The construction of the core carbon skeleton of gallicynoic acid G 56 (Scheme 11) 
was achieved by the alkynylation reaction43 of the known aldehyde 61 with the silyl 
protected hydroxy alkyne 60. The alcohol 68 was obtained as a mixture of 
diastereoisomers. Asymmetric alkynylation reaction of 6043 with 61 under Carreira 
conditions 44 was not pursued due to poor yield of the product. 
Thus, to achieve the (S)-configured hydroxy compound in an optically pure form, 
hence an oxidation-reduction protocol was resorted. Hence, the hydroxy alkyne 68 was 
oxidized with IBX to the corresponding ynone 58. The 13C NMR spectrum of 58 showed 
signal due to the ketone functionality at 187.4 ppm. At this juncture, the stage was set for 
crucial asymmetric reduction reaction (Scheme 9). The (S)-configured alcohol was 
obtained via asymmetric reduction45 of 58 using S-Corey’s catalyst (S-CBS catalyst), in 
94% yield and in 90% de . The diastereoisomeric purity of product 68a was determined by 
chiral HPLC analysis {HPLC (Column: Chiral Pak-IC, 3% isopropanol in n-hexane, flow 
rate: 1 mL/min, 210 nm, tr(major) = 9.922 min, tr(minor) = 10.809 min}. 
The free hydroxy group was protected as its TBS ether (TBSCl/imidazole/CH2Cl2/0 
oC /r.t.) 70. Oxidative deprotection of PMB group in 70 with DDQ in aq. CH2Cl2 produced 
alcohol 72. Swern oxidation of alcohol gave the corresponding aldehyde, which on 
subsequent oxidation with (NaClO2, NaH2PO4.2H2O, 2-methyl-2-butene) in t-butanol fur- 
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nished the TBS protected gallicyanoic acid G 74 in 85% yield. The formation of 19 was 
confirmed by its spectroscopic data. Thus, the 1H NMR spectrum showed a triplet for α-
methylene protons at 2.37 ppm and the 13C-NMR spectrum showed a C=O peak at 179.5 
ppm. 
Finally, the deprotection of the TBS ether with HF (40% aq solution) in MeCN at 
0o C for 2h afforded 1 in 61% yield. The [α]25D, 1H and 13C NMR data of the synthesized 
compound 1 matched with the reported data of gallicynoic acid G 56.27 
OTBS
+ OPMBH
61 n = 1
62 n = 5
OTBS
OH
OPMB
OTBS
O
OPMB
OTBS
OH
OPMB
OTBS
OTBS
OPMB
OTBS
OTBS
OH
OTBS
OTBS
OH
O
OH
OH
OH
O
60 68 n = 169 n = 5
58 n = 1
59 n = 5
68a n = 1
69a n = 5
70 n = 1
71 n = 5
72 n= 1
73 n = 5
74 n = 1
75 n = 5
56 n = 1
57 n = 5
O
n n
nn
n
nn
n
Scheme 11: Reagents and conditions. (a) n-BuLi, THF, - 78 oC, 3h, 68 (75%), 69 (70%); (b) IBX, CH2Cl2, DMSO,
0 oC- r.t., 2h, 58 (79%), 59 (77%); (c) 2-methyl (S )-CBS oxazaborolidine, BH3.SMe2, THF, -30 oC, 1.5h, 68a (94%), 69a
(91%); (d) TBSCl, imidazole, CH2Cl2 , 0 oC - r.t., 2h, 70 (83%), 71 (81%); (e) DDQ, CH2Cl2:H2O, (19 :1), 0 oC, 30 min,
72 (76%), 73 (69%); (f ) (i) (COCl)2, DMSO, Et3N, -78 oC, 1h, 85%; (ii) NaClO2, NaH2PO4. 2H2O, 2-Methyl-2- butene,
tBuOH (1:3), 0 oC- r.t., 12h, 74 (85%), 75 (86%); (g) HF (40%), MeCN, 0 oC, - r.t., 2h, 56 (61%), 57 (58%).
a
b c
d
e f
g
Synthesis of Gallicynoic acids G 56 and H 57
 
Similarly, 60 and 62 were used as the starting materials and subjected to the same 
set of transformations (Scheme 11) to give 57 in comparable yields and in 3.7% overall 
yield.  All the products obtained were characterized by Mass, 1H and 13C NMR the 
spectroscopic data. The data of the synthetic compound 57 were in good agreement with 
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reported values.27  
In conclusion, the stereoselective synthesis of gallicynoic acids G 56 and H 57 
from a common intermediate, the chiral hydroxy alkyne 60 using asymmetric reduction of 
ynones 58 and 59 with CBS reagent as the key step was described in this chapter. 
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